Diagnostic Imaging in the Theranostic Era: From 131I Scintigraphy to the Latest Innovations
A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Oncology".
Deadline for manuscript submissions: 25 November 2025 | Viewed by 81
Special Issue Editors
Interests: theranostics; nuclear medicine therapy; thyroid cancer; neuroendocrine tumours; PET
Special Issue Information
Dear Colleagues,
Nuclear medicine therapies are frequently conducted with radiotracers, exhibiting multiple spectra of radiation emissions, including gamma, beta, and/or alpha rays. The distinctive properties of these isotopes facilitate the concurrent acquisition of diagnostic images and the therapeutic effects. The advent of theranostics coincided with the inception of nuclear medicine therapies in the 1940s, starting with the utilisation of radioiodine in the treatment of thyroid cancer and hyperthyroidism. Subsequent radioiodine-labelled molecules, including 131I-MIBG for neuroblastoma and pheocromocitoma, further exemplify the evolution of theranostics. In recent years, this field has witnessed substantial advancements, exemplified by the approval of therapeutic agents such as 177Lu-oxodotreotide and 177Lu-vipivotide/tetraxetan, accompanied by their respective diagnostic PET tracers. The ability to visualise results, calculate dosimetry, and predict therapeutic effects at a single disease location represents a pivotal innovation. There have also been encouraging research results in relation to other prospective therapeutic targets and radiotracers, which has led to heightened interest in the field of theranostics. Overall, the increased utilisation of nuclear medicine therapies is leading to broader perspectives on their limitations and potential adverse effects.
This Special Issue will provide a platform for sharing expertise, principally through original research, reviews, and perspectives.
Prof. Dr. Francesco Bertagna
Guest Editor
Dr. Pietro Bellini
Guest Editor Assistant
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- theranostic
- nuclear medicine therapy
- thyroid cancer
- DTC
- neuroendocrine tumor
- PET
- PRRT
- prostate cancer
- radiotracers
- dosimetry
- narrative review
- systematic review
- comprehensive review
- radioiodine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
